Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
07:00am, Monday, 13'th May 2024
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock.
The 3 Best Biotech Stocks to Buy in May 2024
06:15am, Thursday, 09'th May 2024
We live in the best of times where life is not capped at 45 or 50 years of age, all thanks to wonderful discoveries in the field of biotechnology. The resources being invested to produce new drugs and
Incyte to Present at Upcoming Investor Conference
08:00am, Thursday, 02'nd May 2024
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:00 a.m. (PDT)
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
12:51pm, Tuesday, 30'th Apr 2024
Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
Incyte Corporation (INCY) Q1 2024 Earnings Call Transcript
11:43am, Tuesday, 30'th Apr 2024
Incyte Corporation (NASDAQ:INCY ) Q1 2024 Earnings Conference Call April 30, 2024 8:00 AM ET Company Participants Ben Strain - Associate VP, IR Hervé Hoppenot - CEO Christiana Stamoulis - CFO Pablo C
Incyte (INCY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
10:35am, Tuesday, 30'th Apr 2024
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to
Incyte misses quarterly profit on weak sales of lead drug
10:25am, Tuesday, 30'th Apr 2024
Incyte Corp on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%.
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
07:00am, Tuesday, 30'th Apr 2024
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs.
Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)
01:45pm, Friday, 26'th Apr 2024
Incyte Corporation shares have underperformed lately, but the company has shown solid growth, profitability, and increased net cash position. Diversification from its blockbuster drug Jakafi has been
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
11:07am, Tuesday, 23'rd Apr 2024
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
07:00am, Tuesday, 23'rd Apr 2024
WILMINGTON, Del. & SAN DIEGO--(BUSINESS WIRE)---- $INCY--Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists.
Incyte to Report First Quarter Financial Results
08:00am, Thursday, 11'th Apr 2024
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 202
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
08:30am, Monday, 01'st Apr 2024
HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY) (“Incyte”) are pleased to an
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 29'th Mar 2024
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?
12:36pm, Thursday, 14'th Mar 2024
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
